BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
2 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
6 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA, Walker GJ; PROTECT ASUC collaborators. Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterol 2022;9:e000763. [DOI: 10.1136/bmjgast-2021-000763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai A, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis 2019;4:31-58. [DOI: 10.1177/2475530318812244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Song EM, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33783045 DOI: 10.1111/jgh.15508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
15 Andrew RE, Lauria A, Puleo FJ, Berg A, Stewart DB Sr. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis. J Surg Res 2017;219:18-24. [PMID: 29078879 DOI: 10.1016/j.jss.2017.05.077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
17 Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2019;71:2-29. [PMID: 30499259 DOI: 10.1002/acr.23789] [Cited by in Crossref: 104] [Cited by in F6Publishing: 77] [Article Influence: 26.0] [Reference Citation Analysis]
18 Bernstein CN, Kornbluth A. Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol 2017;112:1719-21. [PMID: 29109492 DOI: 10.1038/ajg.2017.282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
20 Markovic M, Abramov-Harpaz K, Regev C, Ben-Shabat S, Aponick A, Zimmermann EM, Miller Y, Dahan A. Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA2-Mediated Activation. Int J Mol Sci 2022;23:2673. [PMID: 35269813 DOI: 10.3390/ijms23052673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Markovic M, Ben-shabat S, Nagendra Manda J, Abramov-harpaz K, Regev C, Miller Y, Aponick A, Zimmermann EM, Dahan A. PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics 2022;14:675. [DOI: 10.3390/pharmaceutics14030675] [Reference Citation Analysis]
23 Le Baut G, Kirchgesner J, Amiot A, Lefevre JH, Chafai N, Landman C, Nion I, Bourrier A, Delattre C, Martineau C, Sokol H, Seksik P, Nguyen Y, Marion Y, Lebreton G, Carbonnel F, Viennot S, Beaugerie L; Saint Antoine IBD Network. A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1602-1610.e1. [PMID: 31927106 DOI: 10.1016/j.cgh.2019.12.036] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, Ranjan R, Cooper B, Goodoory V, Ching HL, Jayasooriya N, Brooks J, Dhar A, Shenoy AH, Limdi JK, Butterworth J, Allen PB, Samuel S, Moran GW, Shenderey R, Parkes G, Lobo A, Kennedy NA, Subramanian S, Raine T. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50:675-683. [PMID: 31456297 DOI: 10.1111/apt.15456] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
25 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
26 Heron V, Loftus EV Jr. Nonbiologic Immune Suppression in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:731-8. [PMID: 33121692 DOI: 10.1016/j.gtc.2020.07.003] [Reference Citation Analysis]
27 Liu YJ, Fan H, Zhen WW, Yu X, Chen JT, Wang CD. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis. Medicine (Baltimore) 2018;97:e11440. [PMID: 30095612 DOI: 10.1097/MD.0000000000011440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Eronen H, Ilus T, Jussila A, Huhtala H, Collin P, Oksanen P. Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids. Scand J Gastroenterol 2021;56:234-8. [PMID: 33496198 DOI: 10.1080/00365521.2020.1867892] [Reference Citation Analysis]
29 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
30 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
31 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
33 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
34 Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112. [PMID: 33101457 DOI: 10.1177/1756284820954112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
36 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
37 Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis 2021;27:451-7. [PMID: 32572468 DOI: 10.1093/ibd/izaa088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
39 Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119 [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, Sparrow MP, Connell WR, Moore GT, Radford-Smith G, Van Langenberg DR, De Cruz P. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol 2018;33:1347-52. [PMID: 29266456 DOI: 10.1111/jgh.14072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
41 Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
42 Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord 2021;14:17562864211035542. [PMID: 34457039 DOI: 10.1177/17562864211035542] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Reference Citation Analysis]
44 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
45 Brown SR, Fearnhead NS, Faiz OD, Abercrombie JF, Acheson AG, Arnott RG, Clark SK, Clifford S, Davies RJ, Davies MM, Douie WJP, Dunlop MG, Epstein JC, Evans MD, George BD, Guy RJ, Hargest R, Hawthorne AB, Hill J, Hughes GW, Limdi JK, Maxwell-Armstrong CA, O'Connell PR, Pinkney TD, Pipe J, Sagar PM, Singh B, Soop M, Terry H, Torkington J, Verjee A, Walsh CJ, Warusavitarne JH, Williams AB, Williams GL, Wilson RG; ACPGBI IBD Surgery Consensus Collaboration. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20 Suppl 8:3-117. [PMID: 30508274 DOI: 10.1111/codi.14448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
46 Wu D, Yang Z, Zhao C, Yao L. Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12657. [PMID: 30313056 DOI: 10.1097/MD.0000000000012657] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Dong C, Metzger M, Holsbø E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther 2020;51:8-33. [DOI: 10.1111/apt.15592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
48 Aggarwal A, Sabol T, Vaziri H. Update on the Use of Biologic Therapy in Ulcerative Colitis. Curr Treat Options Gastroenterol 2017;15:155-67. [PMID: 28120279 DOI: 10.1007/s11938-017-0120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
49 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Reference Citation Analysis]
51 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
52 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, Scharl M, Spalinger MR. Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflamm Bowel Dis 2021:izab063. [PMID: 33847343 DOI: 10.1093/ibd/izab063] [Reference Citation Analysis]
54 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
55 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Calabrese E, Monteleone G. Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. JCM 2022;11:1679. [DOI: 10.3390/jcm11061679] [Reference Citation Analysis]
56 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
57 Verma A, Varma S, Freedberg DE, Axelrad JE. A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 33606139 DOI: 10.1007/s10620-021-06877-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Candido FD, Fiorino G, Spadaccini M, Danese S, Spinelli A. Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets 2019;20:1356-62. [PMID: 31465283 DOI: 10.2174/1389450120666190426165325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
60 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
62 Niu W, Chen X, Xu R, Dong H, Yang F, Wang Y, Zhang Z, Ju J. Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. Carbohydr Polym 2021;254:117189. [PMID: 33357839 DOI: 10.1016/j.carbpol.2020.117189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
63 Dulai PS, Raffals LE, Hudesman D, Chiorean M, Cross R, Ahmed T, Winter M, Chang S, Fudman D, Sadler C, Chiu EL, Ross FL, Toups G, Murad MH, Sethuraman K, Holm JR, Guilliod R, Levine B, Buckey JC Jr, Siegel CA. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Aliment Pharmacol Ther 2020;52:955-63. [PMID: 32745306 DOI: 10.1111/apt.15984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
65 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
66 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Reference Citation Analysis]
67 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
68 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
69 Dulai PS, Buckey JC Jr, Raffals LE, Swoger JM, Claus PL, OʼToole K, Ptak JA, Gleeson MW, Widjaja CE, Chang JT, Adler JM, Patel N, Skinner LA, Haren SP, Goldby-Reffner K, Thompson KD, Siegel CA. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol 2018;113:1516-23. [PMID: 29453383 DOI: 10.1038/s41395-018-0005-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
70 Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. Dig Dis 2018;36:106-12. [PMID: 29050007 DOI: 10.1159/000481815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Yamagami H, Nishida Y, Nagami Y, Hosomi S, Yukawa T, Otani K, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis. Rom J Intern Med 2017;55:151-7. [PMID: 28222041 DOI: 10.1515/rjim-2017-0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
72 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 36] [Article Influence: 27.0] [Reference Citation Analysis]
73 Matson J, Ramamoorthy S, Lopez NE. The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. J Clin Med 2021;10:3362. [PMID: 34362144 DOI: 10.3390/jcm10153362] [Reference Citation Analysis]
74 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Biancone L, Calabrese E, Monteleone G. Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. J Clin Med 2021;10:5413. [PMID: 34830694 DOI: 10.3390/jcm10225413] [Reference Citation Analysis]
75 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
76 Dulai PS, Sandborn WJ, Murphy J. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1170-1179.e10. [PMID: 32437872 DOI: 10.1016/j.cgh.2020.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Chen L, Gao Y, Zhang Z, Sun M, Yang W, Liu Z, Jiang X. Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients. Oncotarget 2018;9:15027-35. [PMID: 29599923 DOI: 10.18632/oncotarget.24541] [Reference Citation Analysis]
78 Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE, Cullen G, Doherty GA. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis. J Clin Gastroenterol 2018;52:e48-52. [PMID: 28737646 DOI: 10.1097/MCG.0000000000000884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
79 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Jairath V. Hyperbaric Oxygen for Hospitalized patients with Ulcerative Colitis. American Journal of Gastroenterology 2018;113:1432-4. [DOI: 10.1038/s41395-018-0224-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Philippou A, Rizvi A, Steinlauf A. Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine. Case Rep Gastroenterol 2021;15:147-53. [PMID: 33708063 DOI: 10.1159/000512426] [Reference Citation Analysis]
82 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
83 Yamamoto T, Carvello M, Lightner AL, Spinelli A, Kotze PG. Up-to-date surgery for ulcerative colitis in the era of biologics. Expert Opin Biol Ther. 2020;20:391-398. [PMID: 31948294 DOI: 10.1080/14712598.2020.1718098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Bernardo S, Fernandes SR, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia LA. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:541-6. [PMID: 30085135 DOI: 10.1093/ibd/izy256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
85 Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 2019;71:5-32. [PMID: 30499246 DOI: 10.1002/art.40726] [Cited by in Crossref: 135] [Cited by in F6Publishing: 102] [Article Influence: 33.8] [Reference Citation Analysis]
86 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
87 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
88 D'Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. J Crohns Colitis 2020;14:883-5. [PMID: 32579173 DOI: 10.1093/ecco-jcc/jjaa028] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]